SCHEMBL21836668

SCHEMBL21836668

CCn1nc2c(c1C(=O)c1cc(Br)c(O)c(Br)c1)COCC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 11/20 0.35
TTR P02766 4/20 0.34
EYA3 Q99504 3/20 0.34
CYP2C9 P11712 2/20 0.34
ESR1 P03372 2/20 0.34
CYP2C19 P33261 2/20 0.34
EYA2 O00167 1/20 0.34
MEN1 O00255 1/20 0.34
ABCC4 O15439 1/20 0.34
PLIN1 O60240 1/20 0.34
NR1I2 O75469 1/20 0.34
USP2 O75604 1/20 0.34
ABCB11 O95342 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
ALB P02768 1/20 0.34
NR3C1 P04150 1/20 0.34
CYP1A2 P05177 1/20 0.34
PGR P06401 1/20 0.34
POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24288712 0.91 ROCK2 (0.32) SLC22A12
SCHEMBL22344794 0.83 POLB (0.40) SLC22A12TTREYA3CYP2C9ESR1
SCHEMBL24289263 0.82 TNKS2 (0.35) SLC22A12EYA3ESR1LMNAMAPT
SCHEMBL21836666 0.77 UGCG (0.44) USP2ALDH1A1LMNAMAPTHPGD
SCHEMBL24288761 0.75 POLB (0.34) SLC22A12MEN1ALDH1A1LMNAPOLB
SCHEMBL24289267 0.74 ALDH1A1 (0.37) ALDH1A1POLBCYP3A4MAPTHPGD
SCHEMBL21176888 0.69 SLC22A12 (0.47) SLC22A12TTREYA3CYP2C9ESR1
SCHEMBL21836673 0.68 F12 (0.31) HTR2AHTR2BF12
SCHEMBL21192222 0.68 MEN1 (0.39) SLC22A12TTREYA3CYP2C9ESR1
SCHEMBL22612484 0.67 SLC22A12 (0.36) SLC22A12TTREYA3CYP2C9ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
CN-108484600-B URAT1 inhibitors for promoting uric acid excretion 江苏新元素医药科技有限公司 2022-12-13 CN disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885TTR 2936/4885EYA3 2625/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885TTR 2936/4885EYA3 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.